Screening and intervention: A strategy in type 2 diabetes?;Screening og intervention: En strategi ved type 2-diabetes?

Ugeskrift for Laeger

Volumn 164, Issue 16, 2002, Pages 2135-2139

  Jørgensen, Torben ^a   Glümer, Charlotte ^a   Borch Johnsen, Knut ^a  

^a Center for Sygdomsforebyggelse   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HUMAN; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; METHODOLOGY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; SCREENING TEST; COST BENEFIT ANALYSIS; COST OF ILLNESS; DENMARK; ECONOMICS; MASS SCREENING; MEDICAL ETHICS; ORGANIZATION AND MANAGEMENT; REVIEW;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DENMARK; DIABETES MELLITUS, TYPE 2; ETHICS, MEDICAL; HUMANS; MASS SCREENING;

EID: 4243942787     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Global burden of diabetes, 1995-2025
2. Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes
3. Inter99, a population based study of cardiovascular risk factors in individuals with unknown diabetes mellitus and impaired glucose tolerance
4. Diabetic retinopathy
5. The prevalence and incidence of low-extremity amputation in a diabetic population
6. The incidence of end-stage renal disease in type 1 and type 2 diabetes mellitus
7. Trends in diabetes and diabetes complications
8. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trial; PRECARD and the Copenhagen Risk
9. Economic consequences of diabetes mellitus in the U.S. in 1997
10. Undiagnosed NIDDM: Clinical and public health issues
11. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance and normal glucose tolerance
12. Report of the expert committee on the diagnosis and classification of diabetes mellitus
13. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus
14. Type 2-diabetes og det metaboliske syndrom - Diagnostik og behandling
15. Prospects for research in diabetes mellitus
16. Glucose tolerance and cardiovascular mortality
17. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk)
18. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis
19. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults
20. New diagnostic criteria for diabetes mellitus - Will they change the phenotype of the diabetic subjects?
21. Screening for type 2 diabetes
22. Relationship between fasting plasma glucose and glycosylated hemoglobin: Potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria
23. Performance of an NIDDM screening questionnaire based on symptoms and risk factors
24. The ADDITION study: Proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening
25. Diabetes risk score: Toward earlier detection of type 2 diabetes in general practice
26. The scope of screening
27. Inter99. A populationbased intervention among persons at high risk for cardiovascular disease
28. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33)
29. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS38)
30. Prevention of type 2 diabetes mellitus by changes in life-style among subjects with impaired glucose tolerance
31. Effect of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study
32. Diabetes screening practices among individuals aged 45 years or older
33. Hypertension labelling and sense of well being
34. The psychological impact of screening for risk of coronary heart disease in primary care settings
35. The psychological impact of cardiovascular screening and intervention in primary care: A problem of false reassurance?
36. The cost-effectiveness of screening for type 2 diabetes
37. Estimating the microvascular benefit of screening for type 2 diabetes mellitus